NCT06378866 2026-04-20
DIVINE
Mayo Clinic
Phase 2 Recruiting
Clinical Trials
11 trialsNCT06991556 2026-04-16
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Novartis
Phase 2 Recruiting
NCT02225704 2026-04-13
Radium-223 in Combination With Enzalutamide
Cancer Trials Ireland
Phase 2 Completed
NCT02960022 2026-04-13
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Astellas Pharma Inc
Phase 2 Recruiting
NCT03869762 2026-04-13
DICE
Cancer Trials Ireland
Phase 2 Terminated
NCT07287150 2026-04-08
InavoPC
Hoffmann-La Roche
Phase 2 Recruiting
NCT06632977 2026-04-07
PREDICT
Alliance for Clinical Trials in Oncology
Phase 2 Recruiting
NCT04363164 2026-04-06
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT03899155 2026-04-01
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2 Recruiting
NCT06734130 2026-04-01
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT06096870 2026-03-25
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting